New roles for dopamine D
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
12
04
2018
accepted:
10
12
2018
revised:
17
09
2018
pubmed:
11
1
2019
medline:
15
5
2021
entrez:
11
1
2019
Statut:
ppublish
Résumé
Although long-studied in the central nervous system, there is increasing evidence that dopamine (DA) has important roles in the periphery including in metabolic regulation. Insulin-secreting pancreatic β-cells express the machinery for DA synthesis and catabolism, as well as all five DA receptors. In these cells, DA functions as a negative regulator of glucose-stimulated insulin secretion (GSIS), which is mediated by DA D
Identifiants
pubmed: 30626912
doi: 10.1038/s41380-018-0344-6
pii: 10.1038/s41380-018-0344-6
pmc: PMC6616020
mid: NIHMS1516428
doi:
Substances chimiques
Receptors, Dopamine D2
0
Receptors, Dopamine D3
0
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2070-2085Subventions
Organisme : NIMH NIH HHS
ID : T32 MH018870
Pays : United States
Organisme : NIDA NIH HHS
ID : F32 DA044696
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH093672
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS075222
Pays : United States
Organisme : NIDA NIH HHS
ID : K08 DA031241
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH054137
Pays : United States
Références
Fleischhacker WW, Siu CO, Boden R, Pappadopulos E, Karayal ON, Kahn RS et al. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. Int J Neuropsychopharmacol. 2013;16:987–95.
Fabrazzo M, Monteleone P, Prisco V, Perris F, Catapano F, Tortorella A, et al. Olanzapine is faster than haloperidol in inducing metabolic abnormalities in schizophrenic and bipolar patients. Neuropsychobiology. 2015;72:29–36.
pubmed: 26337616
doi: 10.1159/000437430
Freyberg Z, Aslanoglou D, Shah R, Ballon JS. Intrinsic and antipsychotic drug-induced metabolic dysfunction in schizophrenia. Front Neurosci. 2017;11:432.
pubmed: 28804444
pmcid: 5532378
doi: 10.3389/fnins.2017.00432
Rajkumar AP, Horsdal HT, Wimberley T, Cohen D, Mors O, Borglum AD, et al. Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: a Danish population-based cohort study. Am J Psychiatry. 2017;174:686–94.
pubmed: 28103712
doi: 10.1176/appi.ajp.2016.16040442
Karam CS, Ballon JS, Bivens NM, Freyberg Z, Girgis RR, Lizardi-Ortiz JE, et al. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol Sci. 2010;31:381–90.
pubmed: 20579747
pmcid: 3635536
doi: 10.1016/j.tips.2010.05.004
Ballon JS, Pajvani U, Freyberg Z, Leibel RL, Lieberman JA. Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends Endocrinol Metab. 2014;25:593–600.
Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157:514–20.
pubmed: 10739409
doi: 10.1176/appi.ajp.157.4.514
Kern A, Albarran-Zeckler R, Walsh HE, Smith RG. Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism. Neuron. 2012;73:317–32.
pubmed: 22284186
pmcid: 3269786
doi: 10.1016/j.neuron.2011.10.038
Suzuki M, Hurd YL, Sokoloff P, Schwartz JC, Sedvall G. D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res. 1998;779:58–74.
pubmed: 9473588
doi: 10.1016/S0006-8993(97)01078-0
Rubi B, Ljubicic S, Pournourmohammadi S, Carobbio S, Armanet M, Bartley C, et al. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J Biol Chem. 2005;280:36824–32.
pubmed: 16129680
doi: 10.1074/jbc.M505560200
Simpson N, Maffei A, Freeby M, Burroughs S, Freyberg Z, Javitch J, et al. Dopamine-mediated autocrine inhibitory circuit regulating human insulin secretion in vitro. Mol Endocrinol. 2012;26:1757–72.
pubmed: 22915827
pmcid: 3458225
doi: 10.1210/me.2012-1101
Ustione A, Piston DW. Dopamine synthesis and D3 receptor activation in pancreatic beta-cells regulates insulin secretion and intracellular [Ca(2 + )] oscillations. Mol Endocrinol. 2012;26:1928–40.
pubmed: 22918877
pmcid: 3487623
doi: 10.1210/me.2012-1226
Garcia-Tornadu I, Ornstein AM, Chamson-Reig A, Wheeler MB, Hill DJ, Arany E, et al. Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. Endocrinology. 2010;151:1441–50.
pubmed: 20147524
doi: 10.1210/en.2009-0996
Rosati G, Maioli M, Aiello I, Farris A, Agnetti V. Effects of long-term L-dopa therapy on carbohydrate metabolism in patients with Parkinson’s disease. Eur Neurol. 1976;14:229–39.
pubmed: 1278195
doi: 10.1159/000114744
Ericson LE, Hakanson R, Lundquist I. Accumulation of dopamine in mouse pancreatic B-cells following injection of L-DOPA. Localization to secretory granules and inhibition of insulin secretion. Diabetologia. 1977;13:117–24.
pubmed: 404204
doi: 10.1007/BF00745138
Zern RT, Bird JL, Feldman JM. Effect of increased pancreatic islet norepinephrine, dopamine and serotonin concentration on insulin secretion in the golden hamster. Diabetologia. 1980;18:341–6.
pubmed: 6998806
doi: 10.1007/BF00251017
Ustione A, Piston DW, Harris PE. Minireview: Dopaminergic regulation of insulin secretion from the pancreatic islet. Mol Endocrinol. 2013;27:1198–207.
pubmed: 23744894
pmcid: 3725340
doi: 10.1210/me.2013-1083
Moritz AE, Free RB, Sibley DR. Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds. Cell Signal. 2018;41:75–81.
pubmed: 28716664
doi: 10.1016/j.cellsig.2017.07.003
Diaz-Torga G, Feierstein C, Libertun C, Gelman D, Kelly MA, Low MJ, et al. Disruption of the D2 dopamine receptor alters GH and IGF-I secretion and causes dwarfism in male mice. Endocrinology. 2002;143:1270–9.
pubmed: 11897683
doi: 10.1210/endo.143.4.8750
Kelly MA, Rubinstein M, Asa SL, Zhang G, Saez C, Bunzow JR, et al. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron. 1997;19:103–13.
pubmed: 9247267
doi: 10.1016/S0896-6273(00)80351-7
Wang GJ, Volkow ND, Fowler JS. The role of dopamine in motivation for food in humans: implications for obesity. Expert Opin Ther Targets. 2002;6:601–9.
pubmed: 12387683
doi: 10.1517/14728222.6.5.601
Garcia-Tornadu I, Perez-Millan MI, Recouvreux V, Ramirez MC, Luque G, Risso GS, et al. New insights into the endocrine and metabolic roles of dopamine D2 receptors gained from the Drd2 mouse. Neuroendocrinology. 2010;92:207–14.
pubmed: 20975260
doi: 10.1159/000321395
Iturriza FC, Thibault J. Immunohistochemical investigation of tyrosine-hydroxylase in the islets of Langerhans of adult mice, rats and guinea pigs. Neuroendocrinology. 1993;57:476–80.
pubmed: 8100618
doi: 10.1159/000126394
Persson-Sjogren S, Forsgren S, Taljedal IB. Tyrosine hydroxylase in mouse pancreatic islet cells, in situ and after syngeneic transplantation to kidney. Histol Histopathol. 2002;17:113–21.
pubmed: 11813861
Takayanagi M, Watanabe T. Immunocytochemical colocalizations of insulin, aromatic L-amino acid decarboxylase, dopamine beta-hydroxylase, S-100 protein and chromogranin A in B-cells of the chicken endocrine pancreas. Tissue Cell. 1996;28:17–24.
pubmed: 8907725
doi: 10.1016/S0040-8166(96)80040-1
Ganic E, Johansson JK, Bennet H, Fex M, Artner I. Islet-specific monoamine oxidase A and B expression depends on MafA transcriptional activity and is compromised in type 2 diabetes. Biochem Biophys Res Commun. 2015;468:629–35.
pubmed: 26546820
doi: 10.1016/j.bbrc.2015.11.002
Maffei A, Marie Segal A, Alvarez-Perez JC, Garcia-Ocana A, Harris P. Anti-incretin, anti-proliferative action of dopamine on beta-cells. Mol Endocrinol. 2015;29:542–57.
Merglen A, Theander S, Rubi B, Chaffard G, Wollheim CB, Maechler P. Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells. Endocrinology. 2004;145:667–78.
pubmed: 14592952
doi: 10.1210/en.2003-1099
Romanova IV, Derkach KV, Mikhrina AL, Sukhov IB, Mikhailova EV, Shpakov AO. The leptin, dopamine and serotonin receptors inhypothalamic POMC-neurons of normal and obese rodents. Neurochem Res. 2018;43:821–837.
Newman AH, Grundt P, Cyriac G, Deschamps JR, Taylor M, Kumar R, et al. N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. J Med Chem. 2009;52:2559–70.
pubmed: 19331412
pmcid: 2760932
doi: 10.1021/jm900095y
Xiao J, Free RB, Barnaeva E, Conroy JL, Doyle T, Miller B, et al. Discovery, optimization, and characterization of novel D2 dopamine receptor selective antagonists. J Med Chem. 2014;57:3450–63.
pubmed: 24666157
pmcid: 4315423
doi: 10.1021/jm500126s
Herrera PL. Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages. Development. 2000;127:2317–22.
pubmed: 10804174
doi: 10.1242/dev.127.11.2317
Bello EP, Mateo Y, Gelman DM, Noain D, Shin JH, Low MJ, et al. Cocaine supersensitivity and enhanced motivation for reward in mice lacking dopamine D2 autoreceptors. Nat Neurosci. 2011;14:1033–8.
pubmed: 21743470
pmcid: 3175737
doi: 10.1038/nn.2862
Jung MY, Skryabin BV, Arai M, Abbondanzo S, Fu D, Brosius J, et al. Potentiation of the D2 mutant motor phenotype in mice lacking dopamine D2 and D3 receptors. Neuroscience. 1999;91:911–24.
pubmed: 10391470
doi: 10.1016/S0306-4522(98)00705-2
Carter JD, Dula SB, Corbin KL, Wu R, Nunemaker CS. A practical guide to rodent islet isolation and assessment. Biol Proceed Online. 2009;11:3–31.
doi: 10.1007/s12575-009-9021-0
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8.
pubmed: 11846609
doi: 10.1006/meth.2001.1262
Feigin A, Fukuda M, Dhawan V, Przedborski S, Jackson-Lewis V, Mentis MJ, et al. Metabolic correlates of levodopa response in Parkinson’s disease. Neurology. 2001;57:2083–8.
pubmed: 11739830
doi: 10.1212/WNL.57.11.2083
Aslanoglou D, George EW, Freyberg Z. Homogeneous time-resolved forster resonance energy transfer-based assay for detection of insulin secretion. J Vis Exp. 2018;135:e57531.
Farino ZJ, Morgenstern TJ, Vallaghe J, Gregor N, Donthamsetti P, Harris PE, et al. Development of a rapid insulin assay by homogenous time-resolved fluorescence. PLoS ONE. 2016;11:e0148684.
pubmed: 26849707
pmcid: 4743966
doi: 10.1371/journal.pone.0148684
Li X, Wu X, Camacho R, Schwartz GJ, LeRoith D. Intracerebroventricular leptin infusion improves glucose homeostasis in lean type 2 diabetic MKR mice via hepatic vagal and non-vagal mechanisms. PLoS ONE. 2011;6:e17058.
pubmed: 21379576
pmcid: 3040739
doi: 10.1371/journal.pone.0017058
Zaafar DK, Zaitone SA, Moustafa YM. Role of metformin in suppressing 1,2-dimethylhydrazine-induced colon cancer in diabetic and non-diabetic mice: effect on tumor angiogenesis and cell proliferation. PLoS ONE. 2014;9:e100562.
pubmed: 24971882
pmcid: 4074064
doi: 10.1371/journal.pone.0100562
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.
pubmed: 3899825
doi: 10.1007/BF00280883
Olofsson CS, Gopel SO, Barg S, Galvanovskis J, Ma X, Salehi A, et al. Fast insulin secretion reflects exocytosis of docked granules in mouse pancreatic B-cells. Pflug Arch. 2002;444:43–51.
doi: 10.1007/s00424-002-0781-5
Barg S, Lindqvist A, Obermuller S. Granule docking and cargo release in pancreatic beta-cells. Biochem Soc Trans. 2008;36:294–9.
pubmed: 18481945
doi: 10.1042/BST0360294
Feldman JM, Chapman B. Characterization of pancreatic islet monoamine oxidase. Metabolism. 1975;24:581–8.
pubmed: 1092954
doi: 10.1016/0026-0495(75)90138-9
Uchino H, Kanai Y, Kim DK, Wempe MF, Chairoungdua A, Morimoto E, et al. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol. 2002;61:729–37.
pubmed: 11901210
doi: 10.1124/mol.61.4.729
Khunweeraphong N, Nagamori S, Wiriyasermkul P, Nishinaka Y, Wongthai P, Ohgaki R, et al. Establishment of stable cell lines with high expression of heterodimers of human 4F2hc and human amino acid transporter LAT1 or LAT2 and delineation of their differential interaction with alpha-alkyl moieties. J Pharmacol Sci. 2012;119:368–80.
pubmed: 22850614
pmcid: 7128428
doi: 10.1254/jphs.12124FP
Camargo SM, Vuille-dit-Bille RN, Mariotta L, Ramadan T, Huggel K, Singer D, et al. The molecular mechanism of intestinal levodopa absorption and its possible implications for the treatment of Parkinson’s disease. J Pharmacol Exp Ther. 2014;351:114–23.
pubmed: 25073474
doi: 10.1124/jpet.114.216317
Sulzer D, Cragg SJ, Rice ME. Striatal dopamine neurotransmission: regulation of release and uptake. Basal ganglia. 2016;6:123–48.
pubmed: 27141430
pmcid: 4850498
doi: 10.1016/j.baga.2016.02.001
Pivonello R, Ferone D, Lombardi G, Colao A, Lamberts SW, Hofland LJ. Novel insights in dopamine receptor physiology. Eur J Endocrinol. 2007;156:S13–21.
pubmed: 17413183
doi: 10.1530/eje.1.02353
Kongpracha P, Nagamori S, Wiriyasermkul P, Tanaka Y, Kaneda K, Okuda S, et al. Structure-activity relationship of a novel series of inhibitors for cancer type transporter L-type amino acid transporter 1 (LAT1). J Pharmacol Sci. 2017;133:96–102.
pubmed: 28242177
doi: 10.1016/j.jphs.2017.01.006
Koller WC, Rueda MG. Mechanism of action of dopaminergic agents in Parkinson’s disease. Neurology. 1998;50:S11–14.
pubmed: 9633680
doi: 10.1212/WNL.50.6_Suppl_6.S11
Kostrzewa RM. Dopamine receptor supersensitivity. Neurosci Biobehav Rev. 1995;19:1–17.
pubmed: 7770190
doi: 10.1016/0149-7634(94)00019-W
Lopez Vicchi F, Luque GM, Brie B, Nogueira JP, Garcia Tornadu I, Becu-Villalobos D. Dopaminergic drugs in type 2 diabetes and glucose homeostasis. Pharmacol Res. 2016;109:74–80.
pubmed: 26748034
doi: 10.1016/j.phrs.2015.12.029
Guo N, Guo W, Kralikova M, Jiang M, Schieren I, Narendran R, et al. Impact of D2 receptor internalization on binding affinity of neuroimaging radiotracers. Neuropsychopharmacology. 2010;35:806–17.
pubmed: 19956086
doi: 10.1038/npp.2009.189
Gangarossa G, Espallergues J, Mailly P, De Bundel D, de Kerchove d’Exaerde A, Herve D, et al. Spatial distribution of D1R- and D2R-expressing medium-sized spiny neurons differs along the rostro-caudal axis of the mouse dorsal striatum. Front Neural Circuits. 2013;7:124.
pubmed: 23908605
pmcid: 3725430
Armando I, Konkalmatt P, Felder RA, Jose PA. The renal dopaminergic system: novel diagnostic and therapeutic approaches in hypertension and kidney disease. Transl Resd. 2015;165:505–11.
doi: 10.1016/j.trsl.2014.07.006
Tayebati SK, Lokhandwala MF, Amenta F. Dopamine and vascular dynamics control: present status and future perspectives. Curr Neurovasc Res. 2011;8:246–57.
pubmed: 21722093
doi: 10.2174/156720211796558032
Zhang MZ, Harris RC. Antihypertensive mechanisms of intra-renal dopamine. Curr Opin Nephrol Hypertens. 2015;24:117–22.
pubmed: 25594544
pmcid: 4651846
doi: 10.1097/MNH.0000000000000104
Choi MR, Kouyoumdzian NM, Rukavina Mikusic NL, Kravetz MC, Roson MI, Rodriguez Fermepin M, et al. Renal dopaminergic system: Pathophysiological implications and clinical perspectives. World J Nephrol. 2015;4:196–212.
pubmed: 25949933
pmcid: 4419129
doi: 10.5527/wjn.v4.i2.196
Wang X, Villar VA, Armando I, Eisner GM, Felder RA, Jose PA. Dopamine, kidney, and hypertension: studies in dopamine receptor knockout mice. Pediatr Nephrol. 2008;23:2131–46.
pubmed: 18615257
pmcid: 3724362
doi: 10.1007/s00467-008-0901-3
Zeng C, Armando I, Luo Y, Eisner GM, Felder RA, Jose PA. Dysregulation of dopamine-dependent mechanisms as a determinant of hypertension: studies in dopamine receptor knockout mice. Am J Physiol Heart Circ Physiol. 2008;294:H551–569.
pubmed: 18083900
doi: 10.1152/ajpheart.01036.2007
Morla L, Edwards A, Crambert G. New insights into sodium transport regulation in the distal nephron: Role of G-protein coupled receptors. World J Biol Chem. 2016;7:44–63.
pubmed: 26981195
pmcid: 4768124
doi: 10.4331/wjbc.v7.i1.44
Mitok KA, Freiberger EC, Schueler KL, Rabaglia ME, Stapleton DS, Kwiecien NW et al. Islet proteomics reveals genetic variation in dopamine production resulting in altered insulin secretion. J Biol Chem. 2008;293:5860–5877.
Borelli MI, Rubio M, Garcia ME, Flores LE, Gagliardino JJ. Tyrosine hydroxylase activity in the endocrine pancreas: changes induced by short-term dietary manipulation. BMC Endocr Disord. 2003;3:2.
pubmed: 12659644
pmcid: 153518
doi: 10.1186/1472-6823-3-2
Vazquez P, Robles AM, de Pablo F, Hernandez-Sanchez C. Non-neural tyrosine hydroxylase, via modulation of endocrine pancreatic precursors, is required for normal development of beta cells in the mouse pancreas. Diabetologia. 2014;57:2339–47.
pubmed: 25082160
pmcid: 4181516
doi: 10.1007/s00125-014-3341-6
Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev. 2004;56:331–49.
pubmed: 15317907
doi: 10.1124/pr.56.3.1
Cheng Q, Beltran VD, Chan SM, Brown JR, Bevington A, Herbert TP. System-L amino acid transporters play a key role in pancreatic beta-cell signalling and function. J Mol Endocrinol. 2016;56:175–87.
pubmed: 26647387
doi: 10.1530/JME-15-0212
Carranza A, Musolino PL, Villar M, Nowicki S. Signaling cascade of insulin-induced stimulation of L-dopa uptake in renal proximal tubule cells. Am J Physiol Cell Physiol. 2008;295:C1602–1609.
pubmed: 18842830
doi: 10.1152/ajpcell.00090.2008
Eldrup E, Moller SE, Andreasen J, Christensen NJ. Effects of ordinary meals on plasma concentrations of 3,4-dihydroxyphenylalanine, dopamine sulphate and 3,4-dihydroxyphenylacetic acid. Clin Sci. 1997;92:423–30.
doi: 10.1042/cs0920423
Eldrup E, Richter EA. DOPA, dopamine, and DOPAC concentrations in the rat gastrointestinal tract decrease during fasting. Am J Physiol Endocrinol Metab. 2000;279:E815–22.
pubmed: 11001763
doi: 10.1152/ajpendo.2000.279.4.E815
Goldstein DS, Eisenhofer G, Kopin IJ. Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther. 2003;305:800–11.
pubmed: 12649306
doi: 10.1124/jpet.103.049270
Goldstein DS, Swoboda KJ, Miles JM, Coppack SW, Aneman A, Holmes C, et al. Sources and physiological significance of plasma dopamine sulfate. J Clin Endocrinol Metab. 1999;84:2523–31.
pubmed: 10404831
doi: 10.1210/jcem.84.7.5864
Eldrup E, Richter EA, Christensen NJDOPA. norepinephrine, and dopamine in rat tissues: no effect of sympathectomy on muscle DOPA. Am J Physiol. 1989;256:E284–287.
pubmed: 2493196
Beaulieu JM, Espinoza S, Gainetdinov RR. Dopamine receptors - IUPHAR Review 13. Br J Pharmacol. 2015;172:1–23.
pubmed: 25671228
doi: 10.1111/bph.12906
Leggio GM, Bucolo C, Platania CB, Salomone S, Drago F. Current drug treatments targeting dopamine D3 receptor. Pharmacol Ther. 2016;165:164–77.
pubmed: 27343365
doi: 10.1016/j.pharmthera.2016.06.007
Newman AH, Beuming T, Banala AK, Donthamsetti P, Pongetti K, LaBounty A, et al. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. J Med Chem. 2012;55:6689–99.
pubmed: 22632094
pmcid: 3415572
doi: 10.1021/jm300482h
Ford CP. The role of D2-autoreceptors in regulating dopamine neuron activity and transmission. Neuroscience. 2014;282:13–22.
pubmed: 24463000
doi: 10.1016/j.neuroscience.2014.01.025
Mims RB, Scott CL, Modebe OM, Bethune JE. Prevention of L-dopa-induced growth hormone stimulation by hyperglycemia. J Clin Endocrinol Metab. 1973;37:660–3.
pubmed: 4749441
doi: 10.1210/jcem-37-5-660
Sandyk R. The relationship between diabetes mellitus and Parkinson’s disease. Int J Neurosci. 1993;69:125–30.
pubmed: 8082998
doi: 10.3109/00207459309003322
Furman BL, Wilson GA. The effects of levodopa on plasma glucose in two strains of rat. Eur J Pharmacol. 1979;55:241–6.
pubmed: 456422
doi: 10.1016/0014-2999(79)90190-0
Hahn M, Chintoh A, Giacca A, Xu L, Lam L, Mann S, et al. Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model. Schizophr Res. 2011;131:90–95.
pubmed: 21696923
doi: 10.1016/j.schres.2011.06.004
Lako IM, van den Heuvel ER, Knegtering H, Bruggeman R, Taxis K. Estimating dopamine D(2) receptor occupancy for doses of 8 antipsychotics: a meta-analysis. J Clin Psychopharmacol. 2013;33:675–81.
pubmed: 23948784
doi: 10.1097/JCP.0b013e3182983ffa
Kopf D, Gilles M, Paslakis G, Medlin F, Lederbogen F, Lehnert H, et al. Insulin secretion and sensitivity after single-dose amisulpride, olanzapine or placebo in young male subjects: double blind, cross-over glucose clamp study. Pharmacopsychiatry. 2012;45:223–8.
pubmed: 22426845
doi: 10.1055/s-0031-1301365
Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen HL, Rickels K. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes. 2013;62:3232–40.
pubmed: 23835329
pmcid: 3749337
doi: 10.2337/db13-0430
Kowalchuk C, Castellani L, Chintoh A, Remington G, Giacca A, Hahn M. Antipsychotics and glucose metabolism: how brain and body collide. Am J Physiol Endocrinol Metab. 2019;316:E1–15.
Hahn MK, Wolever TM, Arenovich T, Teo C, Giacca A, Powell V, et al. Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls. J Clin Psychopharmacol. 2013;33:740–6.
pubmed: 24100786
doi: 10.1097/JCP.0b013e31829e8333